2022 annual financial data
Immix Biopharma 2022 Net margin
Direct answer
Net margin was 9.19%.
Operating income was -8,218,948 USD and net income was -8,229,713 USD.
Operating cash flow was -7,408,303 USD.
Get free Immix Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- -89,517,000 USD
- Operating income
- -8,218,948 USD
- Net income
- -8,229,713 USD
- Operating cash flow
- -7,408,303 USD